Company Filing History:
Years Active: 2018
Title: Innovations by Cornelius Kloeck in Tissue Transglutaminase Modulation
Introduction
Cornelius Kloeck is an accomplished inventor based in Munich, Germany. He has made significant contributions to the field of biomedical research, particularly in the modulation of tissue transglutaminase (TG2) activation in various diseases. His innovative work aims to address inflammatory disorders through novel compositions and methods.
Latest Patents
Kloeck holds a patent titled "Modulation of tissue transglutaminase activation in disease." This patent focuses on compositions and methods for modulating the physiological activation of TG2. The methods described can include inhibiting the activity of TG2 associated with inflammatory disorders such as sepsis, ischemic reperfusion injury, and renal fibrosis.
Career Highlights
Cornelius Kloeck is affiliated with Leland Stanford Junior University, where he continues to advance his research in the biomedical field. His work has garnered attention for its potential impact on treating various inflammatory conditions.
Collaborations
Kloeck has collaborated with notable researchers, including Chaitan Khosla and Thomas DiRaimondo. These partnerships have further enriched his research endeavors and contributed to the advancement of knowledge in his area of expertise.
Conclusion
Cornelius Kloeck's innovative work in the modulation of tissue transglutaminase activation represents a significant advancement in the treatment of inflammatory disorders. His contributions continue to shape the future of biomedical research and therapeutic development.